Treatment of chronic pain in patients with temporomandibular joint disorders Musculoskeletal Diseases
Conditions
Interventions
All participants will receive a 5-day virtual reality treatment, and a 5-day audio treatment with identical contents. The sequence of receiving the treatment will be randomized according to a 1:1 rat
Sponsors
University of Maryland, Baltimore
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age (18-75 years old) 2. English speaker (written and spoken) 3. Temporal Mandibular Disorder (TMD) for at least 3 months 4. TMD Grade Chronic Pain Scale (GCPS) =1 5. TMD Screening from HP-00068315 2016 and after
Exclusion criteria
Exclusion criteria: 1. Present or past degenerative neuromuscular disease 2. Cardiovascular, neurological diseases, pulmonary abnormalities, kidney disease, liver disease, history of cancer within past 3 years 3. Any personal (or family first degree) history of mania, schizophrenia, or other psychoses 4. Severe psychiatric condition (e.g. schizophrenia, bipolar disorders, autism) leading to hospitalization within the last 3 years. 5. Lifetime alcohol/drug dependence or alcohol/drug abuse in past 3 months 6. Pregnancy or breast feeding 7. Color-blindness 8. Impaired or uncorrected hearing 9. Any facial trauma that has occurred in the last 6 weeks 10. History of a severe facial trauma in the last 2-3 months 11. Conditions that would interfere with the VR mask placement (e.g. trauma, burn, infection) 12. Known history of severe motion sickness
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Daily pain intensity levels will be measured using visual analogue scale (VAS) from 0=no pain at all to 100=maximum tolerable pain. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Daily pain unpleasantness, anxiety, mood will be measured using VAS from 0=no pain unpleasantness/no anxiety at all/extremely bad to 100=maximum pain unpleasantness/maximum tolerable anxiety/extremely good. 2. Weekly pain behavior, pain interference, anxiety, and sleep disturbances will be measured using Patient Reported Outcome Measurement Information Systems (PROMIS) tools. | — |
Countries
United States of America
Outcome results
None listed